Trade names from 'zavedos®' to 'zarcio®' - Electronic medicinal guide TALKDRUGS

A B AT D D E F З AND Y TO L M H ABOUT P R FROM T Have F X C H W E YU I
5 9 L
Capsules of 5 mg, 10 mg and 25 mg.
Capsules containing 100 mg of miglustat.

Powder for the preparation of concentrate for the preparation of solution for infusions, 2000 mg + 500 mg.

AstraZeneca UK Ltd United Kingdom

Eye drops 0.25 mg / ml.

Cream for external use 2%.
Vaginal suppository 300 mg.

Tablets, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg.

Tablets dispersible in the oral cavity, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg.

The coated tablets are 325 mg + 37.5 mg.

Concentrate for the preparation of a solution for infusions of 25 mg / ml.

Tablets, film-coated 10 mg, 20 mg.

Film coated tablets 200 mg.

Solution for infusion 200mg / 100ml.

Tablets, coated with a film membrane prolonged action of 400 mg, 800 mg.


Solution for intravenous and intramuscular injection 25 mg / ml.

Tablets, film-coated, 200 mg, 400 mg.

Solution for intravenous and subcutaneous administration, 30 million units / 0.5 ml, 48 million units / 0.5 ml.
Sandoz GmbH Austria